Brief: Transgene Updates On Clinical Data

Transgene SA

07/09/2022 16:58

Sept 7 (Reuters) - Transgene SA  TRNG.PA :
    * POSITIVE READOUTS FOR TRANSGENE'S CLINICAL STAGE
CANDIDATES
GENERATED BY ITS TWO INNOVATIVE PLATFORMS, WITH FURTHER CLINICAL
DATA EXPECTED IN SECOND HALF OF 2022
    * FINANCIAL VISIBILITY UNTIL END OF 2023
    * BT-001 (INVIR.IO™ PLATFORM) - INITIAL PHASE I DATA
DEMONSTRATED
GOOD TOLERABILITY AND FIRST SIGNS OF ANTITUMOR ACTIVITY - PHASE
IB (BT-001 IN COMBINATION WITH PEMBROLIZUMAB) EXPECTED TO START
IN SECOND HALF OF 2022
    * TG4050 (MYVAC® PLATFORM) - NEW POSITIVE PHASE I DATA
PRESENTED
AT AACR AND ASCO - ADDITIONAL DATA FROM TWO PHASE I TRIALS TO BE
COMMUNICATED IN H2 2022
    * TG4001- RESULTS FROM INTERIM ANALYSIS OF RANDOMIZED PHASE
II
TRIAL IN HPV-POSITIVE ANOGENITAL CANCERS TO BE RELEASED IN Q4
2022

Source text for Eikon:  ID:nBwc5Ws9ba 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))